Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Interobserver variability in breast carcinoma grading results in prognostic stage differences.

Rabe K, Snir OL, Bossuyt V, Harigopal M, Celli R, Reisenbichler ES.

Hum Pathol. 2019 Oct 23;94:51-57. doi: 10.1016/j.humpath.2019.09.006. [Epub ahead of print]

PMID:
31655171
2.

Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer.

Gupta S, Neumeister V, McGuire J, Song YS, Acs B, Ho K, Weidler J, Wong W, Rhees B, Bates M, Rimm DL, Bossuyt V.

NPJ Breast Cancer. 2019 Aug 29;5:28. doi: 10.1038/s41523-019-0122-x. eCollection 2019.

3.

Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score.

Wilson PC, Chagpar AB, Cicek AF, Bossuyt V, Buza N, Mougalian S, Killelea BK, Patel N, Harigopal M.

Breast J. 2018 Nov;24(6):976-980. doi: 10.1111/tbj.13117. Epub 2018 Sep 19.

PMID:
30230117
4.

Immunological differences between primary and metastatic breast cancer.

Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, Silber A, Park T, Harigopal M, Pelekanou V, Zhang M, Yan Q, Rimm DL, Bianchini G, Hatzis C, Pusztai L.

Ann Oncol. 2018 Nov 1;29(11):2232-2239. doi: 10.1093/annonc/mdy399.

PMID:
30203045
5.

Increased epigenetic age in normal breast tissue from luminal breast cancer patients.

Hofstatter EW, Horvath S, Dalela D, Gupta P, Chagpar AB, Wali VB, Bossuyt V, Storniolo AM, Hatzis C, Patwardhan G, Von Wahlde MK, Butler M, Epstein L, Stavris K, Sturrock T, Au A, Kwei S, Pusztai L.

Clin Epigenetics. 2018 Aug 29;10(1):112. doi: 10.1186/s13148-018-0534-8.

6.

Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer.

Gupta S, Mani NR, Carvajal-Hausdorf DE, Bossuyt V, Ho K, Weidler J, Wong W, Rhees B, Bates M, Rimm DL.

Lab Invest. 2018 Aug;98(8):1076-1083. doi: 10.1038/s41374-018-0064-1. Epub 2018 Jun 1.

7.

Processing and Reporting of Breast Specimens in the Neoadjuvant Setting.

Bossuyt V.

Surg Pathol Clin. 2018 Mar;11(1):213-230. doi: 10.1016/j.path.2017.09.010. Epub 2017 Dec 11. Review.

PMID:
29413658
8.

Metastatic serous carcinoma presenting as inflammatory carcinoma over the breast-Report of two cases and literature review.

Panse G, Bossuyt V, Ko CJ.

J Cutan Pathol. 2018 Mar;45(3):234-239. doi: 10.1111/cup.13091. Epub 2017 Dec 26. Review.

PMID:
29194708
9.

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D'Alfonso TM, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R; International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25. doi: 10.1016/j.semcancer.2017.10.003. Epub 2017 Oct 9. Review.

10.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Review.

11.

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162. Review.

12.

Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer.

von Wahlde MK, Timms KM, Chagpar A, Wali VB, Jiang T, Bossuyt V, Saglam O, Reid J, Gutin A, Neff C, Lanchbury JS, Hatzis C, Hofstatter E, Pusztai L.

Clin Cancer Res. 2017 Mar 1;23(5):1193-1199. doi: 10.1158/1078-0432.CCR-16-0889. Epub 2016 Sep 6.

13.

Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.

Bossuyt V, Symmans WF.

Ann Surg Oncol. 2016 Oct;23(10):3153-61. doi: 10.1245/s10434-016-5317-x. Epub 2016 Jul 5. Review.

PMID:
27380637
14.

Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients: Results of a Randomized Controlled Trial.

Chagpar AB, Horowitz NR, Killelea BK, Tsangaris T, Longley P, Grizzle S, Loftus M, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin DR, Pusztai L, Davidoff AJ, Gross CP.

Ann Surg. 2017 Jan;265(1):39-44. doi: 10.1097/SLA.0000000000001799.

15.

Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools.

Patel JM, Knopf J, Reiner E, Bossuyt V, Epstein L, DiGiovanna M, Chung G, Silber A, Sanft T, Hofstatter E, Mougalian S, Abu-Khalaf M, Platt J, Shi W, Gershkovich P, Hatzis C, Pusztai L.

Oncotarget. 2016 Apr 19;7(16):22064-76. doi: 10.18632/oncotarget.8017.

16.

The Neoadjuvant Model and Complete Pathologic Response in Breast Cancer: All or Nothing?

Bossuyt V, Hatzis C.

JAMA Oncol. 2016 Jun 1;2(6):760-1. doi: 10.1001/jamaoncol.2015.6509. No abstract available.

PMID:
26914064
17.

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer.

Varadan V, Gilmore H, Miskimen KL, Tuck D, Parsai S, Awadallah A, Krop IE, Winer EP, Bossuyt V, Somlo G, Abu-Khalaf MM, Fenton MA, Sikov W, Harris LN.

Clin Cancer Res. 2016 Jul 1;22(13):3249-59. doi: 10.1158/1078-0432.CCR-15-2021. Epub 2016 Feb 3.

18.

Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.

Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L.

Breast Cancer Res Treat. 2015 Dec;154(3):533-41. doi: 10.1007/s10549-015-3631-9. Epub 2015 Nov 14.

19.

Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancers.

Varadan V, Kamalakaran S, Gilmore H, Banerjee N, Janevski A, Miskimen KL, Williams N, Basavanhalli A, Madabhushi A, Lezon-Geyda K, Bossuyt V, Lannin DR, Abu-Khalaf M, Sikov W, Dimitrova N, Harris LN.

Int J Cancer. 2016 Feb 1;138(3):747-57. doi: 10.1002/ijc.29808. Epub 2015 Aug 31.

20.

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.

Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration.

Mod Pathol. 2015 Sep;28(9):1185-201. doi: 10.1038/modpathol.2015.74. Epub 2015 Jul 24.

21.

A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer.

Chagpar AB, Killelea BK, Tsangaris TN, Butler M, Stavris K, Li F, Yao X, Bossuyt V, Harigopal M, Lannin DR, Pusztai L, Horowitz NR.

N Engl J Med. 2015 Aug 6;373(6):503-10. doi: 10.1056/NEJMoa1504473. Epub 2015 May 30.

22.

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.

Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration.

Ann Oncol. 2015 Jul;26(7):1280-91. doi: 10.1093/annonc/mdv161. Epub 2015 May 27. Review.

23.

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.

Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR, Rimm DL.

Cancer Immunol Res. 2015 Apr;3(4):326-32. doi: 10.1158/2326-6066.CIR-14-0133. Epub 2014 Dec 19.

24.

Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer.

Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V.

Clin Cancer Res. 2014 Dec 1;20(23):5995-6005. doi: 10.1158/1078-0432.CCR-14-1622. Epub 2014 Sep 25.

25.

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.

Cheng H, Bai Y, Sikov W, Sinclair N, Bossuyt V, Abu-Khalaf MM, Harris LN, Rimm DL.

BMC Cancer. 2014 May 8;14:326. doi: 10.1186/1471-2407-14-326.

26.

Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy.

Lindner R, Sullivan C, Offor O, Lezon-Geyda K, Halligan K, Fischbach N, Shah M, Bossuyt V, Schulz V, Tuck DP, Harris LN.

PLoS One. 2013 Nov 18;8(11):e71915. doi: 10.1371/journal.pone.0071915. eCollection 2013.

27.

Cancerous 'floater': a lesson learned about tissue identity testing, endometrial cancer and microsatellite instability.

Bossuyt V, Buza N, Ngo NT, Much MA, Asis MC, Schwartz PE, Hui P.

Mod Pathol. 2013 Sep;26(9):1264-9. doi: 10.1038/modpathol.2013.63. Epub 2013 Apr 5.

28.

Use of p63, a myoepithelial cell marker, in determining the invasiveness of spontaneous mammary neoplasia in a rhesus macaque (Macaca mulatta).

Williams-Fritze MJ, Carlson Scholz JA, Bossuyt V, Booth CJ.

J Am Assoc Lab Anim Sci. 2011 Mar;50(2):252-7.

29.

Molecular predictors of response to therapy for breast cancer.

Galanina N, Bossuyt V, Harris LN.

Cancer J. 2011 Mar-Apr;17(2):96-103. doi: 10.1097/PPO.0b013e318212dee3. Review.

PMID:
21427553
30.

Breast carcinoma with chondroid differentiation: a clinicopathologic study of 21 triple negative (ER-, PR-, Her2/neu-) cases.

Gwin K, Wheeler DT, Bossuyt V, Tavassoli FA.

Int J Surg Pathol. 2010 Feb;18(1):27-35. doi: 10.1177/1066896909332732. Epub 2009 Mar 11.

PMID:
19282292
31.

Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma.

Bossuyt V, Medeiros F, Drapkin R, Folkins AK, Crum CP, Nucci MR.

Int J Gynecol Pathol. 2008 Jul;27(3):390-7. doi: 10.1097/PGP.0b013e3181639a82.

PMID:
18580316
33.

Primary osteosarcoma of the ovary: a case report and literature review.

Fadare O, Bossuyt V, Martel M, Parkash V.

Int J Gynecol Pathol. 2007 Jan;26(1):21-5. Review.

PMID:
17197892
34.

Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.

Bossuyt V, Fadare O, Martel M, Ocal IT, Burtness B, Moinfar F, Leibl S, Tavassoli FA.

Int J Surg Pathol. 2005 Oct;13(4):319-27.

PMID:
16273187
35.

Cyclooxygenase-2 expression in postmastectomy chest wall relapse.

Kim JH, Bossuyt V, Ponn T, Lannin D, Haffty BG.

Clin Cancer Res. 2005 Jul 15;11(14):5199-205.

36.

Early detection of cytotoxic events between hepatic natural killer cells and colon carcinoma cells as probed with the atomic force microscope.

Braet F, Vermijlen D, Bossuyt V, De Zanger R, Wisse E.

Ultramicroscopy. 2001 Nov;89(4):265-73.

PMID:
11766982

Supplemental Content

Loading ...
Support Center